Slashback tonight brings some corrections, clarifications, and updates to previous Slashdot stories, including the demystification of Australia's "Mystery Cat", the US Government backs Microsoft in their battle against Korea, RedHat joins the fun and decides to invest in India's economy, the ICANN community slams the VeriSign deal, and Clinical results from the cancer-killing virus trials - read on for details.
Australia's mystery cat demystified. Bitsy Boffin writes "Back in October Slashdot ran a story from the Herald Sun about the shooting of a mystery "Big Cat" in Australia. At the time the tail (the only part the hunter brought back) of said cat had been sent off for DNA testing. The Herald Sun reports the findings of those DNA tests which show that the mystery cat wasn't a leopard or jaguar, just a really, really big feral cat."
US backs Microsoft in Korean antitrust case. CODiNE writes "Stating that 'Korea's remedy goes beyond what is necessary or appropriate to protect consumers' the Justice Department's antitrust division rejects the recent Korean FTC ruling. 'Sound antitrust policy should protect competition, not competitors, and must avoid chilling innovation and competition even by "dominant" companies.'"
RedHat follows Indian investment trend. An anonymous reader writes "After several other companies have decided to invest in the Indian economy it looks like RedHat will be following suit. According to the article, RedHat plans on hiring about 300 people for an investment of about $20M."
ICANN community slams VeriSign deal. Rob writes to tell us that an overwhelming amount of the ICANN community recently took a stand against a proposed deal that would allow VeriSign to raise the price of .com domain names by up to 50%. VeriSign accused ICANN of illegally "regulating" its business. ICANN had previously blocked services VeriSign wanted to launch on the grounds that they would harm the stability of the internet.
Clinical results from cancer-killing virus. just___giver writes "Results from human clinical trials show that terminally ill patients with aggressive metastasized cancer are receiving benefit from the recently covered virus that kills cancer when it is administered intravenously. They still have higher doses to test in this ongoing study. This safe, naturally occurring, unmodified virus has a remarkable ability to infect and kill cancer cells, without affecting normal, healthy cells. Numerous other third party studies show that the Reovirus should be an important discovery in the treatment of 2/3 of all human cancers. It is patented, easy to manufacture in large quantities, and even increases the effectiveness of conventional chemo and radiation therapy. Numerous phase 2 studies are being planned for 2006." OncolyticsBiotech also has a short video describing the process.